IL6 and cutaneous mastocytosis: None of the reviewed evidence suggests we are ready to treat migraines with cytokine inhibitors directly (as is done in some autoimmune diseases), but it opens the door to research on, say, IL-6 inhibitors or TNF inhibitors in refractory CM.